Concentra 集团
CON
38.54
-0.61
-1.56%
Concentra 集团
US · CON
#2185 按市值排名
上市于 2024
38.54
-0.61
-1.56%
实时 - 追踪5344个代码 - 心跳于481秒前
· 2026-10-16 20:01
✦ 量化股权信号 计算方式说明
涨跌不一/平稳
- 最近一期（2026/Q3）披露持股的机构数量减少了2家。
- 机构持股总比例基本持平。
机构持股
- 机构持股比例
- 91.49% +0.03pp
- 机构数量
- 352 -2
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund78.38%
Individual/Insider6.99%
Hedge Fund4.73%
Private Company3.12%
Public Company1.99%
Sovereign Wealth Fund1.35%
Government Pension Fund0.99%
Insurance Company0.76%
Family Office/Trust0.12%
Other1.58%
主要股东 截至 2026-06-30
T. Rowe Price Group, Inc.
15.75% · 20.08M 股
BlackRock
13.92% · 17.75M 股
Vanguard Portfolio Management, LLC
5.35% · 6.82M 股
Robert Ortenzio
5.21% · 6.65M 股
Vanguard Capital Management, LLC
4.69% · 5.98M 股
State Street Global Advisors
3.80% · 4.84M 股
Estate Of Rocco A. Ortenzio
2.57% · 3.27M 股
Jennison Associates LLC
2.55% · 3.26M 股
Dimensional Fund Advisors
2.53% · 3.23M 股
Geode Capital Management, LLC
2.43% · 3.10M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 26次买入 · 24次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Robert Ortenzio | Chairperson | 5.21% |
| William Newton | Chief Executive Officer | 0.38% |
| Matthew DiCanio | President | 0.27% |
| Thomas Devasia | Executive VP and Chief Marketing & Innovation Officer | 0.09% |
| Douglas McAndrew | Executive VP & COO of West | 0.09% |
| Timothy Ryan | Executive VP & Chief Legal Counsel | 0.09% |
| Su Nelson | Chief Accounting Officer | 0.09% |
| Jonathan Conser | Executive VP and Chief Growth & Customer Officer | 0.09% |
| Gregory Gilbert | Executive VP, Chief Reimbursement & Government Relations Officer | 0.09% |
| John deLorimier | Executive VP and Chief Digital & Data Officer | 0.09% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-08-20 | Robert Ortenzio | Chairperson | Sale to Issuer | -1,000,000 | $34.65 |
| 2026-08-02 | Robert Ortenzio | Chairperson | Open Market Disposition | -130,000 | $31.84 |
| 2026-06-30 | Robert Ortenzio | Chairperson | Open Market Disposition | -130,000 | $30.50 |
| 2026-06-29 | Robert Ortenzio | Chairperson | Intent to Sell (Form 144) | -944 | $29.41 |
| 2026-06-28 | Robert Ortenzio | Chairperson | Intent to Sell (Form 144) | -5,589 | $29.85 |
| 2026-06-25 | Robert Ortenzio | Chairperson | Intent to Sell (Form 144) | -53,527 | $29.64 |
| 2026-05-31 | Robert Ortenzio | Chairperson | Open Market Disposition | -130,000 | $25.00 |
| 2026-05-07 | Robert Ortenzio | Chairperson | Open Market Disposition | -130,000 | $25.00 |
| 2025-12-16 | William Newton | Chief Executive Officer | Other Acquisition | +89,081 | -- |
| 2025-12-16 | William Newton | Chief Executive Officer | Other Disposition | -89,081 | -- |
| 2025-11-25 | Su Nelson | Chief Accounting Officer | Sale to Issuer | -5,903 | $21.04 |
| 2025-11-25 | Gregory Gilbert | Executive VP, Chief Reimbursement & Government Relations Officer | Sale to Issuer | -5,903 | $21.04 |
| 2025-11-25 | John deLorimier | Executive VP and Chief Digital & Data Officer | Sale to Issuer | -6,428 | $21.04 |
| 2025-11-25 | Timothy Ryan | Executive VP & Chief Legal Counsel | Sale to Issuer | -5,903 | $21.04 |
| 2025-11-25 | John Anderson | Chief Medical Officer | Sale to Issuer | -6,540 | $21.04 |
| 2025-11-25 | Thomas Devasia | Executive VP and Chief Marketing & Innovation Officer | Sale to Issuer | -5,903 | $21.04 |
| 2025-11-25 | Matthew DiCanio | President | Sale to Issuer | -17,708 | $21.04 |
| 2025-11-25 | Michael Kosuth | Executive VP & COO of East | Sale to Issuer | -6,449 | $21.04 |
| 2025-11-25 | Giovanni Gallara | Executive VP & Chief Clinical Services Officer | Sale to Issuer | -6,563 | $21.04 |
| 2025-11-25 | Douglas McAndrew | Executive VP & COO of West | Sale to Issuer | -5,903 | $21.04 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:01:05 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
Concentra 集团 讨论区 0 条评论